1. Report Introduction 2. Head and Neck cancer (HNC) Market Overview at a Glance 2.1. Market Share Distribution of Head and Neck cancer (HNC) in 2016 2.2. Market Share Distribution of Head and Neck cancer (HNC) in 2028 3. Disease Background and Overview: Head and Neck cancer (HNC) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Head and Neck cancer (HNC) in 7MM 4.3. Total Prevalent Patient Population of Head and Neck cancer (HNC) in 7MM – By Countries 5. Epidemiology of Head and Neck cancer (HNC) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.1.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.1.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.1.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.1.6. Treatable Cases of the Head and Neck cancer (HNC) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.4.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.4.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.4.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.4.6. Treatable Cases of the Head and Neck cancer (HNC) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.5.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.5.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.5.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.5.6. Treatable Cases of the Head and Neck cancer (HNC) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.6.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.6.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.6.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.6.6. Treatable Cases of the Head and Neck cancer (HNC) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.7.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.7.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.7.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.7.6. Treatable Cases of the Head and Neck cancer (HNC) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.8.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.8.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.8.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.8.6. Treatable Cases of the Head and Neck cancer (HNC) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Head and Neck cancer (HNC) 5.9.3. Sub-Type Specific cases of the Head and Neck cancer (HNC) * 5.9.4. Sex- Specific Cases of the Head and Neck cancer (HNC) * 5.9.5. Diagnosed Cases of the Head and Neck cancer (HNC) 5.9.6. Treatable Cases of the Head and Neck cancer (HNC) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Head and Neck cancer (HNC) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Head and Neck cancer (HNC) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Head and Neck cancer (HNC) : 7MM Market Analysis 12.1. 7MM Market Size of Head and Neck cancer (HNC) 12.2. 7MM Percentage Share of drugs marketed for Head and Neck cancer (HNC) 12.3. 7MM Market Sales of Head and Neck cancer (HNC) by Products 13. Head and Neck cancer (HNC) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Head and Neck cancer (HNC) in United States 13.1.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in United States 13.1.3. Market Sales of Head and Neck cancer (HNC) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Head and Neck cancer (HNC) in Germany 13.2.1.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in Germany 13.2.1.3. Market Sales of Head and Neck cancer (HNC) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Head and Neck cancer (HNC) in France 13.2.2.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in France 13.2.2.3. Market Sales of Head and Neck cancer (HNC) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Head and Neck cancer (HNC) in Italy 13.2.3.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in Italy 13.2.3.3. Market Sales of Head and Neck cancer (HNC) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Head and Neck cancer (HNC) in Spain 13.2.4.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in Spain 13.2.4.3. Market Sales of Head and Neck cancer (HNC) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Head and Neck cancer (HNC) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in United Kingdom 13.2.5.3. Market Sales of Head and Neck cancer (HNC) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Head and Neck cancer (HNC) in Japan 13.3.2. Percentage Share of drugs marketed for Head and Neck cancer (HNC) in Japan 13.3.3. Market Sales of Head and Neck cancer (HNC) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Head and Neck cancer (HNC) in 7MM Table 2: Total Prevalent/Incident Cases of the Head and Neck cancer (HNC) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Head and Neck cancer (HNC) in United States (2016-2028) Table 5: Sex- Specific Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Table 6: Diagnosed Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Table 7: Treatable Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Table 11: Diagnosed Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Table 12: Treatable Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in France (2016-2028) Table 14: Sub-Type Specific cases of the Head and Neck cancer (HNC) in France (2016-2028) Table 15: Sex- Specific Cases of the Head and Neck cancer (HNC) in France (2016-2028) Table 16: Diagnosed Cases of the Head and Neck cancer (HNC) in France (2016-2028) Table 17: Treatable Cases of the Head and Neck cancer (HNC) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Table 21: Diagnosed Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Table 22: Treatable Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Table 26: Diagnosed Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Table 27: Treatable Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Head and Neck cancer (HNC) in UK (2016-2028) Table 30: Sex- Specific Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Table 31: Diagnosed Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Table 32: Treatable Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Table 36: Diagnosed Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Table 37: Treatable Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 42:7MM- Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 45: United States-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 48: Germany-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 51: France-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 54: Italy-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 57: Spain-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 60:UK-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Table 63: Japan-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Head and Neck cancer (HNC) in 7MM Figure 2: Total Prevalent/Incident Cases of the Head and Neck cancer (HNC) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Head and Neck cancer (HNC) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Figure 6: Diagnosed Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Figure 7: Treatable Cases of the Head and Neck cancer (HNC) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Figure 12: Treatable Cases of the Head and Neck cancer (HNC) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Head and Neck cancer (HNC) in France (2016-2028) Figure 15: Sex- Specific Cases of the Head and Neck cancer (HNC) in France (2016-2028) Figure 16: Diagnosed Cases of the Head and Neck cancer (HNC) in France (2016-2028) Figure 17: Treatable Cases of the Head and Neck cancer (HNC) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Figure 22: Treatable Cases of the Head and Neck cancer (HNC) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Figure 27: Treatable Cases of the Head and Neck cancer (HNC) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Head and Neck cancer (HNC) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Figure 31: Diagnosed Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Figure 32: Treatable Cases of the Head and Neck cancer (HNC) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Figure 37: Treatable Cases of the Head and Neck cancer (HNC) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 42:7MM- Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 45: United States-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 48: Germany-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 51: France-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 54: Italy-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 57: Spain-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 60:UK-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Head and Neck cancer (HNC) in USD MM (2016-2028) Figure 63: Japan-Market Share Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Head and Neck cancer (HNC) by Therapies in USD MM (2016-2028)